Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: systematic review. | 2022 | Head & Neck |
First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a network meta-analysis and cost-effectiveness analysis. | 2022 | Frontiers in Oncology |
The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with stage III/IV unresectable melanoma: a systematic review and meta‑analysis. | 2022 | Journal of Cancer Research and Therapeutics |
Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. | 2022 | BMJ Open Ophthalmology |
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. | 2021 | Therapeutic Advances in Medical Oncology |
Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: systematic review and meta-analysis. | 2021 | PLoS One |
Chemotherapy in focus: a meta-analysis confronts immunotherapy in the treatment of advanced melanoma. | 2021 | Critical Reviews in Oncology/Hematology |
Systematic review and meta‑analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti‑PD‑1 progression: a systematic review and meta‑analysis. | 2021 | Clinical & Translational Oncology |
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer. | 2021 | Cochrane Database of Systematic Reviews |
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. | 2021 | NICE |
Nivolumab plus ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis. | 2020 | Cancers |
Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. | 2020 | Frontiers in Oncology |
Immune checkpoint inhibitors in advanced acral melanoma: a systematic review. | 2020 | Frontiers in Oncology |
First-line treatments for advanced renal cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. | 2020 | Therapeutic Advances in Medical Oncology |
Economic evaluation of systemic treatments for advanced melanoma: a systematic review. | 2020 | Value in Health |
Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma. | 2020 | JAMA Network Open |
Targeted therapy for metastatic renal cell carcinoma. | 2020 | Cochrane Database of Systematic Reviews |
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: a Bayesian network analysis. | 2019 | EBioMedicine |
The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non–small cell lung cancer and melanoma: network meta-analysis and systematic review. | 2019 | Frontiers in Pharmacology |
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). | 2018 | Cochrane Database of Systematic Reviews |
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. | 2018 | BMJ |
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. | 2018 | BMJ |
Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis. | 2018 | Journal of Immunology Research |
Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review. | 2018 | Melanoma Management |
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. | 2017 | PLoS One |
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. | 2017 | Medicine |
Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. | 2017 | BMJ Open |
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review. | 2017 | Cancer Treatment Reviews |
Treatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. | 2017 | Clinical Oncology |
Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. | 2017 | Expert Review of Anticancer Therapy |
Risk of treatment-related mortality in cancer patients treated with ipilimumab: a systematic review and meta-analysis. | 2017 | European Journal of Cancer |
Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. | 2017 | Clinical, Cosmetic and Investigational Dermatology |
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. | 2017 | Medicine |